Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.

ABSTRACT:

Background

Myelofibrosis (MF) can be primary (PMF) or secondary (SMF), with PMF driven by Janus kinases-signal transducer and activator of transcription proteins (JAK-STAT) pathway activation due to Janus kinase 2 (JAK2), the thrombopoietin receptor gene (myeloproliferative leukemia virus oncogene (MPL)), or calreticulin (CALR) mutations. Nearly 50% of PMF patients experience anemia (hemoglobin (Hb) < 10 g/dL), often worsened by JAK inhibitors like ruxolitinib and fedratinib. Momelotinib, an oral ACVR1, JAK1, and JAK2 inhibitor, improves anemia, symptoms, and splenomegaly, likely through hepcidin regulation. This review evaluates its efficacy and safety, with a focus on anemia.

Methods

A systematic review and meta-analysis were conducted following the Pr

SUBMITTER: Al-Nusair J 

PROVIDER: S-EPMC12404109 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature